icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
Fhtu4Q6krffZFybV